Enlivex’s Allocetra Shows Promise in Osteoarthritis Trial

Enlivex (ENLV) has released an update.

Enlivex Therapeutics Ltd. has reported promising interim results from their Phase I/II trial of Allocetra in treating severe knee osteoarthritis, demonstrating significant pain reduction and a high rate of surgery avoidance with a favorable safety profile. The study revealed a 64% average reduction in pain and 89% of patients choosing not to proceed with knee replacement surgery after treatment. These findings offer hope for a new therapeutic approach for individuals struggling with this debilitating condition.

For further insights into ENLV stock, check out TipRanks’ Stock Analysis page.